Ampligen

Start

Disclaimer

Sitemap alfabetisch Classificatie  Cvs-ME CVS Adolescenten CVS ME Algemeen
CVS-Archieven CVS Behand-Onderzoek CVS Bloedtesten CVS Congressen CVS Diëten CVS Geneesheren
CVS Geneesmiddelen CVS Immunologie CVS-Juridisch CVS Kenmerken CVS Massage CVS Pijn-Pain
CVS-Psychisch CVS Orthomoleculair CVS Osteopathie CVS Terminologie CVS Verwante ziektes CVS- Virussen

CVS -Acupunctuur CVS Alternatief CVS Chinese geneeswijzen CVS Chiropractor CVS-Cultuur
CVS-Fibromyalgie CVS-Homeopathie CVS-Kinesiologie CVS Kinesitherapie CVS Manuele therapie CVS-Publicaties
CVS Seksualiteit CVS-Tandhygiëne CVS-Toerisme CVS-Websites CVS Werelddag Antwerp  

  

CVS Verz. maatschappijen CVS-Verzekeringen CVS-Verz.-geneeskunde Gewaarborgd inkomen CVS Gew.inkomen

CVS Medische expertise CVS Minnel.med.expertise Medische Maffia    

Start
Omhoog

 

Ampligen:

 

 

http://www.cfids-cab.org/cfs-inform/
Ampligen/ampligen.html

What is Ampligen ?

http://www.hetalternatief.org/
Ampligen%20FDA%202008%20324.htm

Hemispherx verstrekt FDA antwoorden op aanvullende vragen

 

 

http://money.cnn.com/news/newsfeeds/articles/
globenewswire/179462.htm

Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx"), announced that it received a Complete Response Letter from the U.S. Food and Drug Administration ("FDA") which describes specific additional recommendations related to the Ampligen(R) NDA. In accordance with its 2008 "Complete Response" procedure, the FDA reviewers determined that they cannot approve the application in its present form and provided specific recommendations to address the outstanding issues

http://www.immunesupport.com/library/showarticle.cfm?id=7538&T=CFIDS_FM

Major Late-Round Ampligen® Trial Recruits in Seven States

http://www.secinfo.com/dSSer.2b.htm

Hemispherx Biopharma Inc

http://www.cfs-news.org/ampwsj00.htm

Ampligen vs.Asensio in the Wall Street Journal :This article describes the financial battle between the manufacturer of Ampligen and financial short-seller Manuel Asensio, as reported by the Wall Street Journal, Monday, June 26, 2000. Ampligen is an experimental drug being developed for treatment of chronic fatigue syndrome and HIV and other diseases.

http://www.cfs-news.org/ampligen.htm   

Ampligen and CFS

http://listserv.nodak.edu/cgi-bin/wa.exe?A2=ind0502a&L=co-cure&F=&S=&P=6132

Ampligen [polyI:polyC12U] is a mismatched double-stranded RNA that acts by inducing interferon production (immunomodulator) and by activating an intracellular enzyme (RNase-L) against viral RNA transcripts (antiviral).

http://www.fatigatio.de/43

Studien zur Wirksamkeit van Ampligen bei cfs gehen weiter

http://www.immunesupport.com/library/
showarticle.cfm/ID/3667/T/CFIDS_FM/
searchtext/International%20conference/
  

Chronic Fatigue Syndrome News: Special Ampligen Reports

http://www.hemispherx.net/content/ftp/   

Hemispherx Drug Candidates

http://www.hemispherx.net/content/corp/   

Hemispherx Code of Ethics

http://www.drlapp.net/research.htm

Ampligen

http://www.ahmf.org/database/ampligen.html

Ampligen Treatment

http://www.immunesupport.com/library/
bulletinarticle.cfm?ID=5346&PROD=PH193

Phase 3 Clinical Trial of Ampligen for Chronic Fatigue Syndrome Completed

http://dspace.dial.pipex.com/comcare/news/
me0056.txt

Canada authorizes Ampligen for chronic
fatigue syndrome

http://www.hemispherx.net/content/rnd/

Ampligen® and Proprietary Drug Portfolio

http://www.fcclinic.com/ampligen.html

Ampligen trial

   

 

 

Artikelen :

 

Ampligen in the Pink

Ampligen en goedkeuring

Ampligen_ Hope For Chronic Fatigue Sufferers

Hemispherx Biopharma inc en beursnieuws

Ampligen®, is a new class of specifically-configured ribonucleic acid (RNA) compounds targeted at such important diseases as Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME), HIV, Hepatitis B, Hepatitis C, and cancers including kidney cancer and metastatic malignant melanoma.

For the patient :See the links to the right for information on Chronic Fatigue Syndrome, HIV, hepatitis B, hepatitis C, renal cell carcinoma, and metastatic malignant melanoma.

Hemispherx presents new data on long-term, post-trial effects of RNA-based Ampligen for CFS